Impel Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system. The Company is rapidly advancing a product pipeline that pairs its proprietary Precision Olfactory Delivery (POD®) technology with well- established therapeutics, including Trudhesa® for the acute treatment of migraine, INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease. To learn more about Impel Pharmaceuticals, please visit our website at http://impelpharma.com.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society
Jun 09, 2022
Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa New Analysis Suggest Patient-Reported Benefits of Long-Term Use with Trudhesa Two Additional Analyses Demonstrate Trudhesa Efficacy Regardless of Current Preventive...
SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an init...
Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022
Trudhesa® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021 Planned initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in 2Q 2022 Financing Agreement with Oaktree Capital Extends Cash Runway...